Q-omics provides the consensus-scored ITGB6 profile across patient tissues and cancer cell-line models. ITGB6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ITGB6 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ITGB6 protein abundance shows 30,171 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight PAAD, KIRC, and GBM as cancer lineages where ITGB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITGB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITGB6 survival associations across molecular data types. ITGB6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITGB6 RNA expression–survival associations across cancer types. High ITGB6 expression shows unfavorable associations in PAAD, LUSC, LIHC, STAD and SKCM, but favorable associations in BLCA. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for ITGB6 RNA expression.
This table summarizes ITGB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ITGB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITGB6 shows lower tumor expression in KIRC, KICH and LUSC and higher tumor expression in HNSC, BLCA and UCEC. The KIRC box plot shows higher ITGB6 RNA expression in normal versus tumor tissue (log2 FC = −3.392, t-test p < 0.001).
This table shows molecular features associated with ITGB6 in patient tissues and cancer cell lines. In patient samples, ITGB6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ITGB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
